Publications by authors named "Tasnim Olatoke"
Lymphangioleiomyomatosis (LAM) is a cystic lung disease that primarily affects women. LAM is caused by the invasion of metastatic smooth muscle-like cells into the lung parenchyma, leading to abnormal cell proliferation, lung remodeling and progressive respiratory failure. LAM cells have TSC gene mutations, which occur sporadically or in people with Tuberous Sclerosis Complex.
View Article and Find Full Text PDFLymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that predominantly affects women. LAM cells carry mutations, causing mTORC1 hyperactivation and uncontrolled cell growth. mTORC1 inhibitors stabilize lung function; however, sustained efficacy requires long-term administration, and some patients fail to tolerate or respond to therapy.
View Article and Find Full Text PDFArticle Synopsis
- Tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) are diseases linked to mutations in TSC1 and TSC2, leading to the growth of tumors in various organs, especially affecting women’s lungs in the case of LAM.
- Recent research using single-cell RNA sequencing in LAM patients revealed that specific genes involved in sphingolipid biosynthesis were activated, with significant increases in key enzymes like acid ceramidase (ASAH1) in TSC2-null cells.
- Combining the enzyme inhibitor ARN14976 with rapamycin showed promise in reducing tumor growth and cell viability in experimental models, pointing toward new therapeutic strategies targeting abnormal sphingolipid pathways in TSC and